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The mammalian intestinal tract is a unique site in which a large portion of our immune
system and the 1014 commensal organisms that make up the microbiota reside in intimate
contact with each other. Despite the potential for inﬂammatory immune responses, this
complex interface contains host immune cells and epithelial cells interacting with the
microbiota in a manner that promotes symbiosis. Due to the complexity of the cell types
and microorganisms involved, this process requires elaborate regulatory mechanisms to
ensure mutualism and prevent disease. While many studies have described critical roles
for protein regulators of intestinal homeostasis, recent reports indicate that non-coding
RNAs are also major contributors to optimal host-commensal interactions. In particular,
there is emerging evidence that microRNAs (miRNAs) have evolved to ﬁne tune host
gene expression networks and signaling pathways that modulate cellular physiology in
the intestinal tract. Here, we review our present knowledge of the inﬂuence miRNAs have
on both immune and epithelial cell biology in the mammalian intestines and the impact this
has on the microbiota.We also discuss a need for further studies to decipher the functions
of speciﬁc miRNAs within the gut to better understand cellular mechanisms that promote
intestinal homeostasis and to identify potential molecular targets underlying diseases such
as inﬂammatory bowel disease and colorectal cancer.
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INTRODUCTION
A major goal of the biomedical research community is to
understand mechanisms that regulate the gut immune system
in a manner that maintains homeostasis, despite the presence
of trillions of bacteria and other microorganisms that reside on
and within the host. Gut homeostasis is deﬁned by a proper
balance of pro-inﬂammatory responses against harmful and/or
invading microbes while tolerating non-invasive and beneﬁcial
microbes (Hooper and Macpherson, 2010). During this state,
healthy proportions of commensals, tolerant immune cells, and
pro-inﬂammatory host cells interact closely with one another.
However, if this balance is disrupted, either by changes to
the composition of the gut microbiota or by alterations to the
host response, diseases can emerge (Round and Mazmanian,
2009).
In order to maintain homeostasis, the host intestinal mucosa
contains distinct regions consisting of various cell types necessary
to respond to antigens in an appropriate manner (Hooper and
Macpherson, 2010; Figure 1). These regions include: the outer and
innermucus layers, inwhich invadingmicrobes become trapped to
prevent spread of infection (Johansson et al., 2011); the epithelial
layer, in which physical and chemical barriers are formed to pre-
vent dissemination of bacteria into underlying tissues (Goto and
Ivanov, 2013; Peterson and Artis, 2014); the lamina propria (LP),
a leukocyte-rich region that lies underneath the epithelium, hous-
ing cells that respond to microbial signals (Duerkop et al., 2009);
and other immune cell-containing gut-associated lymphoid tis-
sues (GALT) such as Peyer’s Patches and mesenteric lymph nodes.
Immune cell-rich gut tissues contain a diverse set of cell types,
both hematopoietic and non-hematopoietic-derived, that play a
role in maintaining healthy interactions with the resident micro-
biota. Some of these cell types are unique to the intestines and
many have distinct functions within the GI tract. Several of these
gut cells have been demonstrated to be required for providing both
defense against pathogens and tolerance to commensals in order
to prevent disease.
The gut microbiota itself heavily inﬂuences proper develop-
ment and function of the intestinal immune system (Round and
Mazmanian, 2009; Hooper et al., 2012; Ivanov and Honda, 2012).
Indeed, germ-free mice display developmental defects within
GALT and intestinal epithelial cells (IECs). One mechanism by
which the microbiota can inﬂuence intestinal immune cells is
via surface and cytoplasmic receptors called pattern recognition
receptors (PRRs) that recognize conserved microbial motifs on
both pathogens and commensals. PRR detection of microbial
products initiates a variety of immune responses and developmen-
tal pathways. One class of PRRs is the toll-like receptors (TLRs),
which signal primarily through the adaptor protein MyD88 to
activate master transcription factors such as NF-κB. In some
cases, gut microbial recognition by the host leads to proin-
ﬂammatory responses resulting in increased gut inﬂammation
(Ivanov et al., 2009). In other situations, activation of cell surface
receptors by commensal products induces tolerogenic responses
(Round et al., 2011; Smith et al., 2013). Additionally, recogni-
tion of commensal and food molecules by PRRs is essential
for the maintenance of intestinal homeostasis (Rakoff-Nahoum
et al., 2004; Abreu, 2010). This demonstrates the importance of
host-commensal interactions in proper immune function and
overall host physiology. While PRRs are but one mechanism
thought to inﬂuence homeostasis, many of the molecular events
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FIGURE 1 | MicroRNAs play important roles within the complex
intestinal immune system.They can be expressed within hematopoietic
cells in response to inﬂammatory signals from pattern recognition receptors
(PRR) and antigen receptors (AR). In this way, miRNAs can regulate immune
responses, including secretion of cytokines, chemokines, and antibodies, all
of which affect intestinal homeostasis. Within intestinal epithelial cells (IECs)
and other non-hematopoietic intestinal cells, miRNAs are expressed in and
regulate pathways involved in secretion of antimicrobial peptides, cell
renewal, and barrier permeability, among others. They also may mediate host
responses to microbial metabolites, which signal to host cells via metabolite
receptors (MR). Many immune signals that induce miRNAs and immune
responses within the gut come from the microbiota. Altered commensal
populations may mediate different miRNA responses and functions within the
intestinal tract.
that mediate crosstalk between host cells and microbiota remain
enigmatic.
MicroRNAs (miRNAs) have recently emerged as important
mediators of immune development and responses. miRNAs are
short (21–25 nucleotide), non-coding RNA molecules that are
most commonly transcribed by RNA polymerase II and pro-
cessed by proteins such as Drosha and Dicer (Winter et al., 2009).
In their mature, RNA-induced silencing complex (RISC)-bound
form, miRNAs bind to and downregulate expression of target
mRNAs by degradation and/or blocking of translation. miRNAs
have been demonstrated to regulate immune responses by modu-
lating gene expression of immune-related genes. In this way, they
modulate the balance between effective inﬂammatory responses
to foreign entities and proper resolution of inﬂammation to
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prevent tissue damage. More than 100 miRNAs are expressed
within leukocytes (O’Connell et al., 2010), and many of these
miRNAs have multiple targets within immune-related pathways,
consistent with an important role in the immune system (Bal-
timore et al., 2008; Lindsay, 2008; O’Connell et al., 2010, 2012;
Chen et al., 2013). Some of the most well-studied miRNAs in the
immune system include miR-155, miR-146a, miRs-17∼92, and
miR-181a (Baltimore et al., 2008). Many of these miRNAs regu-
late key signaling pathways such as Jak/Stat, TLR/MyD88, NF-κB,
and Akt, which are essential for immune responses (O’Connell
et al., 2012). Some miRNAs, such as miR-155, target negative
regulators of the immune response to promote inﬂammation.
Conversely, others, like miR-146a, target positive regulators of
immunity to promote tolerance and resolution of responses.
Despite the large amount of work done over the past decade, not all
targets and functions of miRNAs in the immune system, includ-
ing well-studied miRNAs, have been worked out. Furthermore,
even less is known about miRNAs within the intestinal immune
system.
microRNAs modulate expression of genes involved in micro-
bial recognition and downstream immune activity, and thus may
play an important role within the intestinal immune system
during its interactions with the gut microbiota. Their expres-
sion in various intestinal cell types, including hematopoietic-
derived leukocytes, IECs, and other specialized gut cell types
points to a role in mediating homeostasis with commensal
microbes and overall intestinal health (Figure 1). These non-
coding RNAs function as rheostats to the immune response as
opposed to binary switches as they act to adjust the magni-
tude of gene expression. miRNAs also work in feedback loops,
ensuring that the immune system does not produce inappropri-
ately strong responses while also promoting protective immunity
when needed. In this way, miRNAs themselves can be considered
mediators of homeostasis within the immune system as they
act to buffer inﬂammation. Immune processes within the GI
tract are coordinated differently when compared to other sites
in the body as a result of regulatory mechanisms required to
handle the constant exposure to microbes. Intestinal homeosta-
sis is sensitive to even small disruptions, and therefore miRNAs
make excellent candidate molecules for ﬁne-tuning responses at
this sensitive site. Multiple studies are beginning to demonstrate
the importance of miRNAs within the intestine and identifying
how the microbiota inﬂuences miRNA expression and function
within the GI tract; some of this work will be reviewed here
(Table 1).
miRNAs IN HEMATOPOIETIC-DERIVED GUT IMMUNE CELLS
The function of miRNAs within hematopoietic-derived immune
cells has been well-studied, and it is now clear that miRNAs
are deeply integrated into the molecular networks that govern
mammalian immune responses (Lindsay, 2008; O’Connell et al.,
2010, 2012; Chen et al., 2013). However, relatively few studies
have examined the functions of miRNAs in leukocytes within
the GI tract, where unique subsets of immune cells are known
to reside. Recent investigations indicate that miRNAs also play
important roles in hematopoietic cells within the intestines. For
example, miR-155 was found to be required for protection during
mucosal infection by the intestinal pathogenCitrobacter rodentium
(Clare et al., 2013). miR-155-deﬁcient mice displayed a higher
pathogen burden within the gut, a delayed ability to clear the
bacteria, and a worsened colitis phenotype as a result of infec-
tion. Interestingly, this phenotype was attributed to a defective
intestinal humoral response due to a loss of miR-155 in B cells.
This study demonstrates that miR-155 regulates gut B cells in a
manner similar to its functions in B cells found in other microen-
vironments (Thai et al., 2007; Vigorito et al., 2007); however, a
Table 1 | Selected summary of studied miRNAs and their roles in the intestinal immune system, reviewed in this paper.
miRNA Intestinal role or effect Compartment
and/or cell types involved
miRNA target(s) Reference
miR-155 Induced byTGFβ, decreased IL-2 and IFNγ expression
in lamina propria
LPT cells InducibleT cell
kinase (ITK)
Das et al. (2013)
miR-29 Decreased IL-23/Th17 gut responses, protected from
colitis
Dendritic cells IL-12p40 Brain et al. (2013)
miR-10a MaintainedTreg lineage and prevented plasticity to
other T cell subsets
Peyer’s patchT cells Bcl6 Takahashi et al. (2012)
miR-146a Reduced inﬂammation during intestinal ischemia
reperfusion injury
Intestinal epithelial cells IRAKI Chassin et al. (2012)
miR-122 Increased intestinal permeability when induced with
TNFa
Intestinal epithelial cells Occludin Ye et al. (2011)
miR-124 Associated with protection from pediatric UC Human colonocytes Stat3 Koukos et al. (2013)
miR-21 Overexpressed in intestinal disease, knockout mice
protected from colitis
Whole murine colon Unknown Shi et al. (2013)
miR-143/
mlR-145
Intestinal epithelial regeneration following tissue
injury (DSS)
Mesenchymal cells Igfbp5 Chivukula et al. (2014)
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different study displayed a unique role for miR-155 in the gut.
Upon exposure to TGFβ, miR-155 was found to be signiﬁcantly
upregulated in LP T cells, contrasting with only a modest induc-
tion of miR-155 when peripheral T cells were treated with TGFβ
(Das et al., 2013). Additionally, while miR-155 is known to pro-
mote inﬂammatory responses in many contexts, Das et al. (2013)
observed immune-inhibitory effects of miR-155 in LP T cells, as
evidenced by their intrinsic downregulation of both IL-2 and IFNγ
expression upon induction of miR-155 by TGFβ. Importantly,
gain and loss of function approaches revealed that miR-155 is
indeed a repressor of these cytokines in LP T cells and identiﬁed
a prominent target of miR-155 in LP T cells as inducible T-cell
kinase (ITK), which normally promotes development and effec-
tor function of T cells. This work provides evidence that miR-155
may function uniquely within intestinal LP T cells, in contrast
to its well-studied roles in T cells found at other anatomical
locations.
A unique role for miR-29 was recently demonstrated in den-
dritic cells of the intestine. In this study, the intracellular pattern
recognition receptor NOD2 induced expression of miR-29 in den-
dritic cells (Brain et al., 2013). miR-29 was found to directly target
IL-12p40, which led to the downregulation of IL-23 and Th17
responses in the gut. Consequently, mice lacking miR-29 dis-
played worsened microbial-dependent colitis compared to WT
controls. These data characterized a gut-speciﬁc role for miR-
29, which had previously been shown to target genes involved
in proliferation, differentiation, and ﬁghting bacterial infections
(Ma et al., 2011). These ﬁndings provide additional evidence that
miRNA functions can be unique within the intestinal microen-
vironment compared to their functions in peripheral sites, and
this may also involve their expression and function in distinct cell
types.
miR-10a, a miRNA largely involved in embryonic development
(Lund, 2010), has also been shown to play a distinct role within
in the gut. In Peyer’s Patches, which are located throughout the
small intestine, miR-10a was highly expressed within regulatory
T cells (Tregs; Takahashi et al., 2012). Expression of this miRNA
within inducible Tregs in the Peyer’s Patch constrained their plas-
ticity and prevented conversion into T follicular helper (Tfh) cells.
Takahashi et al. (2012) demonstrated thatmiR-10amaintained the
Treg lineage within the GALT by targeting and downregulating the
Tfh master regulator gene, Bcl6. The biological signiﬁcance of
miR-10a function within Peyer’s Patch Treg cells appears to be the
maintainance of tolerance, and mutations that impair this func-
tion may predispose individuals to intestinal disease. Future work
will determine if the role of miR-10a in preventing Treg plastic-
ity is unique to gut-expressed Tregs or broadly applicable to Tregs
found at extra-intestinal sites.
Altogether, relatively few studies have examined gut-speciﬁc
roles of well-known hematopoietic miRNAs, potentially due to
assumption that their known functions in peripheral sites will
carry over into the GI tract. While this may be true in some cases,
it is possible that expression levels, targets, and the overall func-
tions of miRNAs are distinct in the intestine versus extra-intestinal
sites in the body. Furthermore,miRNAs that appear to play little or
no roles in the systemic immune system may prove to have exclu-
sive functions in unique populations of leukocytes within the gut.
Because hematopoietic-derived immune cells interact heavily with
the microbiota within the intestinal environment, understanding
the roles of miRNAs within gut leukocytes will be key to under-
standing molecular pathways in which the host and microbiota
interact, and this may differ from how a given miRNA functions
in extra-intestinal sites.
miRNAs IN NON-HEMATOPOIETIC-DERIVED GUT CELLS
Intestinal epithelial cells (IECs) are now recognized as non-
hematopoietic cells that exhibit immunological functions, includ-
ing the ability to directly recognize microbial products via PRRs
(Vaishnava et al., 2008) and to secrete mucus (goblet cells)
and antimicrobial peptides (paneth cells) in response to these
microbes. As miRNAs regulate many immunological and develop-
mental pathways, they may have signiﬁcant functional relevance
within IECs.
Generally, disruption of miRNA processing pathways in the
intestinal epithelium results in susceptibility to intestinal infec-
tion. This was demonstrated through the speciﬁc deletion of
Dicer1 within IECs in mice (Dicer1loxP/loxP; Villin-Cre, referred
to as Dicer1IEC mice; McKenna et al., 2010; Biton et al., 2011).
As Dicer is required for the processing of miRNAs into their
mature form, its deletion abolishes miRNA function. These
studies found that the deletion of Dicer from IECs results in
mice with impaired growth, metabolism, and water retention.
Additionally, Dicer1IEC mice displayed a reduction in goblet
cells, an increase in inﬁltrating inﬂammatory immune cells,
and disorganized intestinal architecture. These mice also had
increased intestinal permeability, decreased mucus production,
and decreased Th2 cytokines and factors (Biton et al., 2011). Con-
sequently, Dicer1IEC mice were more susceptible to Tricuris
muris infection and displayed IBD symptoms and inappropri-
ate Th1 responses during infection. Finally, Biton et al. (2011)
revealed that miR-375 was a critical IEC-expressed miRNA that
was required for proper IEC differentiation and that it medi-
ated communication with T cells to induce Th2 responses when
appropriate.
One miRNA that appears to have similar targets in IECs as
compared to other hematopoietic cell types is miR-146a. miR-
146a directly targets essential TLR downstream signaling genes
including TNF receptor associated factor 6 (TRAF6) and inter-
leukin1 receptor-associated kinase 1 (IRAK1) to downregulate
inﬂammation (Boldin et al., 2011; Zhao et al., 2011, 2013). In
a mouse model of intestinal ischemia/reperfusion (I/R) injury,
Chassin et al. (2012) showed that IEC expression of IRAK1 led to
increased inﬂammation and tissue damage. When miR-146a was
induced in IECs in vitro, expression of inﬂammatory chemokines
and the effects of hypoxia were reduced. In vivo, miR-146a
was directly injected into mice or its expression induced by
DIM, and mice showed reduced disease and inﬂammation dur-
ing I/R injury due to miR-146a targeting and downregulating
expression of IRAK1 in IECs. Utilizing conditional knockout
mice to examine the roles of IRAK1 and miR-146a speciﬁ-
cally in IECs during this intestinal injury model, as well as
in other intestinal disease models, would bring about further
understanding of the cellular basis of miR-146a function in
the gut.
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microRNAs within non-hematopoietic cells may also a play a
role in the development of and protection from intestinal can-
cers. The epithelium requires proper signaling mechanisms for
normal development, differentiation, renewal, and repair of the
intestinal tissue (Chivukula et al., 2014). Many of these signaling
pathways require regulation by miRNAs, and colorectal cancer
(CRC) can arise if dysregulated. One study found that miR-143
and miR-145, which are abnormally expressed during human
CRC, are required for proper regeneration of IECs (Chivukula
et al., 2014). When miRs 143 and 145 were deleted, mice were
unable to undergo proper intestinal renewal and wound healing.
The authors found that these miRNAs were expressed speciﬁcally
within the intestinal mesenchyme and that deletion of miRs 143
and 145 from mesenchymal tissue resulted in a similar pheno-
type. Consistent with this, these miRNAs were found to target
IGFBP5, an inhibitor of IGF signaling, which is required for
regeneration of IECs. Thus, miRNAs expressed speciﬁcally within
non-hematopoietic-derived mesenchymal cells are required to
maintain intestinal regeneration and their dysregulation could
result in improper growth and proliferation, potentially giving
rise to intestinal cancers.
Another example, in which known miRNA functions are rele-
vant in IECs, is the interplay of the RNA-binding protein LIN28
and the Let7 family of miRNAs. Let7 miRNA processing has been
shown to be inhibited by LIN28 in models of cellular repro-
gramming, growth, and oncogenesis (Viswanathan and Daley,
2010). One group examined this interaction in the context of
the intestine and found that overexpression of LIN28B in IECs led
to abnormal intestinal architecture, crypt expansion, Paneth cell
loss, and formation of intestinal tumors. (Madison et al., 2013).
A similar phenotype was seen in miR-Let-7c2 and Let-7b deﬁ-
cient mice, indicating a disease-promoting role of LIN28B in
targeting and degrading these miRNAs. Expression of Let-7 in
the intestine reversed the hyperplasia and Paneth cell loss seen in
the LIN28B overexpressing mice. This study indicates that Let-7
miRNAs are important for preventing overgrowth of IECs down-
streamof the oncogenicRNA-binding protein LIN28B. Expression
or modulation of this miRNA family could either prevent or cause
CRCs.
The ability of IECs to form tight junctions is important in
creating an effective barrier between the host and commensal
microbiota. Defective intestinal tight junction barriers are seen in
IBD and other intestinal diseases and result in increased inﬂam-
mation (Ye et al., 2011). Recently, miRNAs have been shown
to play a role in regulating intestinal epithelial tight junction
permeability. For example, Dicer1IEC mice showed decreases
in cells expressing the epithelial tight junction protein, claudin,
and a weakened barrier (McKenna et al., 2010). In another
study, stimulating IECs with TNFα in vitro led to increased
expression of miR-122 (Ye et al., 2011). miR-122 directly targets
occludin mRNA, which encodes a protein that forms intestinal
tight junctions. Thus, expression of miR-122 increased intestinal
epithelial permeability. Mice overexpressing miR-122 displayed
decreased intestinal barrier function as a result of downregulated
occludin expression. In this way, miR-122 may be a valid target
in diseases involved in intestinal barrier and permeability, such
as IBD.
Altogether, miRNAs play pivotal roles in IECs and other
non-hematopoietic-derived intestinal cells, which can contribute
to the protection of the host tissue from pathogenic invaders and
disease. As common immunological pathways are essential within
IECs, miRNAs that regulate these pathways also have relevance
within these non-hematopoietic cells. For example, conditional
deletionof theTLRadaptorproteinMyD88within IECs resulted in
loss of barrier function and defective immunity from commensal
bacteria (Vaishnava et al., 2011; Frantz et al., 2012). Thus, miRNAs
that have known targets in immune signaling pathways down-
stream of MyD88 can also play important regulatory roles within
IECs. Generally, based on the above studies and others, the expres-
sion and function of miRNAs within non-hematopoietic cells of
the intestinal immune system play a large role in maintaining
intestinal homeostasis.
GUT MICROBIOTA AND miRNAs
In discussing the functions and features of the mammalian
intestine, one cannot ignore the large contribution to host phys-
iology by the gut microbiota. It is estimated that approximately
one hundred trillion commensal organisms reside within the
human GI tract (Phillips, 2009; Hooper and Macpherson, 2010).
These microbes are extremely diverse in their taxonomy, com-
munities, and functions. The gut microbiota communicates
directly with the host via the production of metabolites, pep-
tides, and other signaling molecules. MiRNA expression by the
host may play a signiﬁcant role in determining how microbiota-
produced signals are received by the host, and miRNAs may
balance the ﬁne line between maintaining an effective barrier
and preventing inappropriate inﬂammation in response to the
microbiota.
It is known that the microbiota modulates expression of
host genes, as expression proﬁles of WT germ-free (GF) mice
are markedly different from WT speciﬁc pathogen free (SPF)
mice (El Aidy et al., 2013). New studies are beginning to exam-
ine whether this communication between host and microbiota
involves miRNAs. In one such study, GF mice were colonized with
microbiota from SPF mice and their miRNA proﬁle was exam-
ined via microarray (Dalmasso et al., 2011). Nine miRNAs were
differentially expressed in the ileum and colon of SPF-colonized
compared with uncolonized GF mice. This differential expression
of miRNAs within the mouse gut was predicted to alter the expres-
sion of hundreds of miRNA target genes. For example, miR-665,
which was downregulated in SPF-colonized mice compared with
GF mice, targeted the Abcc3 gene (an ATP-binding cassette trans-
porter) in the colon. In a similar study, the differences in miRNA
expression within the cecum between GF and SPF mice were
examined (Singh et al., 2012). Sixteen miRNAs were expressed dif-
ferentially between GF and SPF mice. Upon analyzing networks of
genes involved in intestinal barrier function that may be regulated
by these miRNAs, the authors propose that the gut microbiota
modulates host miRNA genes, which then target and regulate the
intestinal barrier.
In another investigation, the role of the microbiota in regu-
lating host miRNA expression was examined in the context of
Listeria monocytogenes infection (Archambaud et al., 2013). GF
mice had a greater Listeria burden when compared to infected
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SPF mice in multiple tissues. The authors hypothesized that
these higher bacterial counts were due to the lack of micro-
biota, which prime host immune responses via changes in gene
expression. They performed gene expression analysis of protein-
coding and miRNA genes in SPF and GF infected and uninfected
mice and observed that ﬁve miRNAs were downregulated in SPF
mice during infection but not in GF mice. These included miR-
378 and miR-200c. The downregulation of these miRNAs due to
the presence of microbiota led to increased expression of sev-
eral protein-coding genes that were predicted targets of these
miRNAs. Using the set of differentially expressed target mRNA
and their corresponding miRNAs, the authors revealed a miRNA-
mRNAnetwork inwhichmicrobiota-mediatedmiRNAexpression
primed the intestinal immune system to strengthen the barrier and
combat Listeria infection. Additionally, the authors deﬁned the ten
miRNAs, including miR-143 and miR-215, that are most highly
expressed within the ileum of SPF and GF mice before and dur-
ing infection. These miRNAs may be considered ileal “signature”
miRNAs.
While the above studies highlight potential roles for speciﬁc
miRNAs in host-microbiota interactions, further investigation is
necessary to reconcile differences between the studies and to ﬁnd
consensus miRNAs that may be more signiﬁcantly involved in
crosstalk between host gut tissue and the microbes that reside in
this locale. So far, studies have examined miRNA expression pro-
ﬁles within varied intestinal sections; the microenvironments of
these sections are largely different when compared to one another.
Furthermore, these tissues contain a heterogeneous population of
cells, which may not reveal miRNAs involved in host–microbial
interactions within speciﬁc intestinal cell types. Utilizing cell sort-
ing and RNA-sequencing to analyze gene expression may identify
miRNAs that are differentially expressed within speciﬁc and/or
rare gut cell types uponexposure tomicrobes. Additionally, further
experimentation is necessary to understand cellular mechanisms
and biological importance of the candidate miRNAs uncovered in
these studies.
Some work has also been done to begin deﬁning speciﬁc
mechanisms by which miRNAs are induced by products of the
microbiota. In one such investigation, expression of a subset of
miRNAs was downregulated in human colon cells treated with
butyrate, a beneﬁcial short-chain fatty acid (SCFA) derived from
commensal bacteria (Hu et al., 2011). These miRNAs, particu-
larly those of the miR-106b family, were conversely expressed at
high levels in colons of human colon cancer patients. Butyrate
blocked expression of the miR-106b family to allow for increased
expression of p21 in a miRNA-dependent manner. p21 is a
cell cycle arrest protein important in preventing various can-
cers. Importantly, miR-106b reversed the anti-proliferative effects
of butyrate via direct targeting of p21. Thus, a product of the
microbiota regulates gene expression of host miRNAs to prevent
colonic disease and cancer. The cellular mechanism by which
butyrate directly modulates miRNA gene expression has yet to
be investigated.
Another study demonstrated that miR-10a is highly expressed
in the intestines and can be modulated by the gut microbiota
throughTLR signaling on dendritic cells, which suppresses expres-
sion of miR-10a (Xue et al., 2011). In experiments characterizing
relevant targets and pathways, miR-10a directly targeted and
downregulated expression of IL-12/23p40, an important cytokine
for innate inﬂammatory responses in the GI tract. Mice with
colitis had decreased expression of miR-10a and thus high lev-
els of IL-12/23p40. In this instance, the microbiota signals to
the host to downregulate expression of miR-10a, which targets
a portion of host innate immunity. Another miRNA, miR-107,
targeted a component of the IL-23 receptor, IL-23p19 (Xue et al.,
2014). Like miR-10a, the expression of miR-107 was downreg-
ulated by the microbiota, as GF mice showed high levels of
miR-107, which was decreased following microbial colonization.
Mice with colitis displayed low levels of miR-107 and high levels of
IL-23p19, indicating the importance of this miRNA in downregu-
lating inﬂammation in response to commensals. Proper crosstalk
between the gut microbiota and miR-107 in intestinal immune
cells, which targets IL-23p19, can play a role in maintaining
homeostasis.
Overall, signals from the microbiota have the ability to alter
expression of miRNAs. In turn, miRNAs can target immune-
related mRNAs that have the ability to impact responses to
microbes and thus shape commensal communities. Thus, crosstalk
between microbiota and miRNAs is required for shaping intestinal
immune responses and maintaining homeostasis.
miRNAs AND HUMAN INTESTINAL DISEASE
Many human diseases are related to dysregulation of the intesti-
nal immune system and of the microbiota, including allergies,
various autoimmune diseases, and cancers (Round and Mazma-
nian, 2009; Kamada et al., 2013; Sears and Garrett, 2014). One
of the most prominent and well-studied class of intestinal disease
is inﬂammatory bowel disease (IBD). IBD is caused by chronic
and inappropriate inﬂammation within the gastrointestinal tract,
and this affects approximately 1.4 million Americans. Further-
more, CRC risk is signiﬁcantly increased in patients that have IBD
(Neurath, 2014). Together, this has placed a considerable burden
on the healthcare system (Abraham and Cho, 2009). The most
common types of IBD are Crohn’s Disease (CD) and ulcerative
colitis (UC),and eachof these display different causes andpatholo-
gies. Although genetic and environmental factors are known to
play a role in the etiology of IBD subtypes, the speciﬁc fac-
tors that directly cause these diseases are not fully understood.
Furthermore, CD, UC, and other intestinal diseases appear to
display various pathologies, outcomes, and treatment options
depending on the individual (Dalal and Kwon, 2010), emphasiz-
ing the need for more diagnostic and therapeutic reagents in the
clinic.
Recently, miRNA expression proﬁles have been shown to
change in people suffering from IBD. Patients with UC and
CD have distinct miRNA proﬁles that are unique to their dis-
ease stage when compared with healthy controls. This is true for
both intestinal tissue biopsies and peripheral blood (Dalal and
Kwon, 2010; Wu et al., 2011; Pekow and Kwon, 2012; Iborra et al.,
2013; Lin et al., 2014). Among the miRNAs found to have altered
expression during UC and CD were miR-16 (Wu et al., 2010),
miR-146a (Lin et al., 2014), miR-31 (Lin et al., 2014), miR-340∗
(Wu et al., 2011), and miR-199a-5p (Wu et al., 2011). Some of
these miRNA expression proﬁle studies during IBD have been
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summarized in two recent reviews (Dalal and Kwon, 2010; Pekow
and Kwon, 2012). It is important to note that each study has
sampled a different group of patients, disease types and states,
as well as tissue types. This likely explains why there does not
appear to be a common group of miRNAs that are associated
with IBD across all studies. Future work must be done to rec-
oncile the differences in miRNA proﬁles in each study and to
clarify which miRNAs are common or unique to distinct dis-
ease types. These miRNA proﬁles might be used to accurately
diagnose IBD types and predict patient prognoses. Addition-
ally, the concept of utilizing blood miRNAs as biomarkers for
intestinal disease is promising because collection would be non-
invasive. Even so, further experimentation needs to be done to
understand the functional signiﬁcance of altered expression of
speciﬁc miRNAs in various human tissues and cell types during
disease.
The roles of some miRNAs and their targets during IBD and
intestinal disease are beginning to be elucidated. For example,
during active pediatric UC, levels of phosphorylated Stat3 were
increased in colonocytes, and correlated with low expression of
miR-124 in diseased patients (Koukos et al., 2013). Furthermore,
miR-124 directly bound to and downregulated expression of Stat3.
High levels of Stat3 and corresponding low levels of miR-124
were only seen in pediatric patients with active UC and not in
adults, pediatric CD, pediatric inactive UC, nor healthy patients.
This was also observed in mouse models of colitis. Dysregu-
lation of the Stat3 pathway occurs in diseased patients due to
hypermethylation of miR-124. This study implicates miR-124
and the Stat3 pathway as highly relevant potential therapeutic
targets for treatment of pediatric UC. Even so, whether down-
regulation of miR-124 via hypermethylation is a cause or effect
of IBD in children has not yet been elucidated. In another study,
Brain et al. (2013) showed that human CD patients with polymor-
phisms in the NOD2 gene were unable to upregulate expression
of miR-29. In this way, miR-29 could not repress downstream
cytokine signaling pathways that were attributed to worsened dis-
ease. In general, these ﬁndings support the validity of miRNAs
and their experimentally veriﬁed targets as important players in
human IBD.
Single nucleotide polymorphisms (SNPs) in miRNA genes may
also play a role in susceptibility to intestinal diseases (Pekow
and Kwon, 2012; Gazouli et al., 2013). SNPs within miRNAs
could alter their expression, processing, and functional target-
ing. Thus, the presence of certain miRNA SNP variants in
humans can be associated with and may even be functionally
relevant (Jin and Lee, 2013). The rs2910164 SNP within the
miR-146a gene on chromosome 5 has been shown to decrease
mature miR-146a levels and subsequently increase its target genes
(Jazdzewski et al., 2008; Shao et al., 2014). This miRNA SNP
has been implicated in numerous human diseases, including
various cancers (He et al., 2012), papillary thyroid carcinoma
(Jazdzewski et al., 2008), and sepsis (Shao et al., 2014). Even so,
a general consensus within studies and meta-analyses regard-
ing disease associations with rs2910164 has not been reached,
as group size, methods of statistical analysis, and the ethnic
groups sampled can affect the conclusions made in each study.
In relation to the GI tract, this miR-146a SNP was associated
with CD (Gazouli et al., 2013), while no signiﬁcant association
was observed with UC patients (Okubo et al., 2011; Gazouli
et al., 2013). Patients with this SNP variant were also found to
have increased risk of intestinal metaplasia and dysplasia dur-
ing H. pylori infection (Song et al., 2013). Furthermore, this
polymorphism in miR-146a predicted susceptibility to CRC and
disease-speciﬁc survival outcome (Chae et al., 2013; Ma et al.,
2013). MiR-146a downregulates inﬂammation by targeting com-
ponents of theNFκBpathway (Boldin et al., 2011; Zhao et al., 2011,
2013), and these studies suggest that a change in one nucleotide
within this miRNA could alter the intestinal inﬂammatory state
via dysregulation of NFκB and other related pathways. How-
ever, the functional consequences of this polymorphism remain
incompletely understood. Taken together, these ﬁndings provide
evidence that the altered function of immune-related miRNA
genes can inﬂuence the susceptbility to, and outcome during,
intestinal diseases.
As IBD patients carry an increased risk of developing CRC,
miRNAs also have potential as biomarkers, prognostic tools, and
therapeutic targets during cancers of the GI tract. While mul-
tiple factors may inﬂuence CRC, miRNAs have been shown to
play important roles in the molecular pathways that can give
rise to intestinal cancers. These include pathways involved in
inﬂammation, chromatin formation, stem cell signaling, apop-
tosis, and others (Liu and Chen, 2010; Chivukula et al., 2014).
Expression proﬁling has indicated that miR-31, miR-21, and
miR-191 are upregulated (Liu and Chen, 2010), while miR-143,
miR-145, and miR-451 are downregulated in CRC tumors (Liu
and Chen, 2010; Chivukula et al., 2014). Another study, using an
RNA-sequencing approach, found that miR-10a-5p, miR-21-5p,
miR-22-3p, miR-143-3p, and miR-192-5p are among the most
abundantly expressed miRNAs in a CRC cohort (Schee et al.,
2013). A pathway analysis revealed that these altered RNAs could
affect many cellular signaling pathways including Wnt, MAPK,
and TGFβ, all of which are linked to oncogenesis. Animal studies
utilizing genetic manipulation of miRNAs within the intestines
are currently being carried out to understand cellular mecha-
nisms of CRC-related miRNAs that have been found in human
studies, and a recent report has found critical roles for miR-
NAs 143 and 145 in pathways that can lead to CRC (Chivukula
et al., 2014). Although much work remains, it has become clear
that miRNAs within cells of the intestines are relevant during
human IBD, CRC, and other intestinal diseases that stem from
perturbations in intestinal homeostasis. This underscores the
importance of miRNAs in maintaining intestinal homeostasis in
humans.
FUTURE DIRECTIONS AND CONCLUDING REMARKS
In general, these investigations suggest that miRNAs are likely
indispensable regulators of host-commensal interactions that are
required for proper intestinal homeostasis. Because miRNAs
ﬁne-tune targets by downregulating their expression 1.2–4-fold
(O’Connell et al., 2012), they prevent imbalances that eventu-
ally lead to loss of homeostasis and disease. miRNAs may also
prove to be effective drug targets in terms of treating intestinal
diseases. Extensive future studies are required to further deﬁne
speciﬁc mechanisms of miRNA function in intestinal immunity.
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This will unveil how miRNAs inﬂuence the balance between
maintaining beneﬁcial resident microbes and eliminating those
that are harmful within the gut.
Tying together emerging concepts in the miRNA ﬁeld with
those in the GI tract and microbiota ﬁelds will bring about
a comprehensive understanding of cellular processes that con-
trol intestinal homeostasis. One of these novel concepts is the
transfer of miRNAs between cells via exosomes (Stoorvogel,
2012). In the future, it will be important to determine if this
mode of exosomal miRNA transfer occurs and has biological
relevance within the intestines to modify gut homeostasis and
commensal populations. Another emerging concept regarding
the microbiota involves the important role of gut commensals
in contributing to extra-intestinal effects. For example, recent
studies have determined that the gut microbiota can impact
the biology of extra-intestinal sites, such as the brain, heart,
and liver and as a consequence can inﬂuence diseases includ-
ing MS, autism, cardiovascular disease, and obesity (Wang et al.,
2011; Collins et al., 2012; Hsiao et al., 2013; Kamada et al., 2013;
Zhao, 2013); miRNAs may play important roles in the commu-
nication process between host and microbiota at extra-intestinal
sites. miRNAs may also function in cells as they respond to gut
microbial metabolites and other products. Commensal-derived
metabolites, such as short-chain fatty acids (SCFAs) and bile
acids, play important roles in development and function of
immune cells within the gut and can contribute to immunologi-
cal and metabolic phenotypes within the host (Brestoff and Artis,
2013).
miRNAs and host-commensal interactions have been indepen-
dently linked to human development, health, and disease in the
past. Now, as we begin to explore how these systems are integrated,
a greater understanding of how host-commensal interactions are
regulated will undoubtedly emerge. This will provide novel ther-
apeutic insights that will help combat the wide range of diseases
that are related to the gut.
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